OBM Geriatrics is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2024): Submission to First Decision: 6.3 weeks; Submission to Acceptance: 11.4 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Treatments and Management of Menopausal Symptoms: Current Status and Future Challenges
Submission Deadline:
December 15, 2026 (Open)
Submit Now
Guest Editor
Ciro Comparetto,
MD
Department of Obstetrics and Gynecology, Valdisieve Hospital, Pelago, Florence, Italy
Website | E-Mail
Research Interests: Gynecologic oncology; gynecologic surgery; cervical cancer screening and prevention
Co-Editor
Marjan Ghaemi, MD
Assistant Professor of Gynecology and Obstetrics, Vali-e-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran
Website | E-Mail
Research Interests: Women's health; menopause; quality of life; reproduction; gynecology
About This Topic
Menopausal symptoms affect a substantial proportion of women and can significantly impact quality of life during the transition to and beyond menopause. Current treatment strategies include hormonal therapies—recognized as the most effective option for vasomotor symptoms—alongside a growing range of non-hormonal pharmacological agents, lifestyle interventions, and complementary approaches. Despite the availability of multiple therapies, challenges persist related to individualized treatment selection, safety concerns, variable symptom patterns, and gaps in long-term evidence. Emerging treatments, such as neurokinin-3 receptor antagonists, offer promising alternatives for women who cannot or prefer not to use hormone therapy. As life expectancy increases and the demand for personalized care expands, optimizing the management of menopausal symptoms will require integrated, evidence-based strategies and improved access to information and clinical support. Future efforts must focus on refining risk–benefit assessments, addressing disparities in care, and advancing research to support tailored, patient-centered management.
Keywords
Menopause; vasomotor symptoms; hormone therapy; non-hormonal treatments; neurokinin-3 receptor antagonists; women’s health; personalized care; quality of life
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Open Access
Short Communication
Abstract
Narratives and how women interpret their symptoms have always been a part of how menopause is experienced. Today, as women feel more accessible to talk about menopause, new narratives are being formed and negotiated - both to menopause and concerning women becoming older. These different narratives mirror the fact that the transitional phase [...]
|
Abstract
Non Alcoholic Fatty Liver Disease (NAFDL) is a condition in which an individual suffers from an accumulation of fat in the liver. This is a disease condition with a multifactorial etiology. Some potent causes of such conditions are altered thyroid condition, abnormal metabolism in the body due to aging or menopause, or any other hormonal imbal [...]
|
Abstract
In the United States (US), menopause occurs at an average age of 52. Menopausal symptoms tend to be maximal during the few years before and the year after menopause (during perimenopause), except for symptomatic vulvovaginal atrophy, which may worsen over time. Up to 20% of bone density loss occurs during the first 5 years after menopause [...]
|
Lotte Hvas